VSTM

Verastem, Inc.

Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib (VS-6063).

Verastem, Inc. (VSTM) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) B (3.4) A- (3.9) A- (4.1) C+ (2.6) B (3.4)
2026-11-08 B- (3.0) B+ (3.7) A- (3.9) A- (4.0) C+ (2.6) B (3.4)
2026-11-01 B- (2.9) B- (3.0) B- (3.0) B+ (3.8) C+ (2.7) B- (3.1)
2026-10-25 B- (3.0) B- (3.0) B- (3.0) B+ (3.7) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe